Abstract #798656: Real Life Experience of Hydroxychloroquine in Type-2 Diabetes Patients Uncontrolled on a Combination of Metformin and Sulfonylurea for its Glycemic, Anti-Lipid and Anti-Inflammatory Parameters

Introduction. This study aimed at evaluating the efficacy and safety of dapagliflozin in patients with type 2 diabetes (T2D) who also received metformin in clinical practice in Italy. Methods. This was a retrospective observational study and it included data from patients who received dapagliflozin 10 mg once daily in conjunction with metformin for 12 months (DAPA + MET). In those with inadequate glycemic control, insulin or glimepiride was added after 30 days (DAPA + MET + other glucose-lowering drugs). Efficacy assessments included glycosylated hemoglobin (HbA1c) levels at 6 and 12 months, as well as body mass index (BMI) and lipid parameters at 12 months. Safety was also assessed. Results. Data on 66 patients were included. In both groups, HbA1c was significantly reduced at 6 and 12 months compared with baseline and significant reductions in HbA1c were observed at 12 months compared with 6 months. Over the 12-month treatment period, dapagliflozin significantly reduced BMI in both groups. No significant changes in lipid parameters were observed in either group and no detrimental effects on renal function were detected. Conclusions. Dapagliflozin is effective and safe in patients with T2D also receiving metformin. Glycemic control was already achieved with dapagliflozin + metformin, and add-on therapy was not associated with further improvements.

Download Full-text

Inflammatory Activities in Type 2 Diabetes Patients With Co-morbid Angiopathies and Exploring Beneficial Interventions: A Systematic Review

Frontiers in Public Health ◽

10.3389/fpubh.2020.600427 ◽

2021 ◽

Vol 8 ◽

Author(s):

Martin C. Nwadiugwu

Keyword(s):

Type 2 Diabetes ◽

Dietary Supplements ◽

Management Strategies ◽

Cochrane Library ◽

Regular Exercise ◽

Eligibility Criteria ◽

Soluble Rage ◽

Anti Inflammatory ◽

Diabetes Patients

Background: Diabetes is a long-term condition that can be treated and controlled but do not yet have a cure; it could be induced by inflammation and the goal of managing it is to prevent additional co-morbidities and reduce glycemic fluctuations. There is a need to examine inflammatory activities in diabetes-related angiopathies and explore interventions that could reduce the risk for future outcome or ameliorate its effects to provide insights for improved care and management strategies.Method: The study was conducted in Embase (1946–2020), Ovid Medline (1950–2020), and PubMed databases (1960–2020) using the PICO framework. Primary studies (randomized controlled trials) on type 2 diabetes mellitus and inflammatory activities in diabetes-related angiopathies were included. Terms for the review were retrieved from the Cochrane library and from PROSPERO using its MeSH thesaurus qualifiers. Nine articles out of 454 total hits met the eligibility criteria. The quality assessment for the selected study was done using the Center for Evidence-Based Medicine Critical Appraisal Sheet.Results: Data analysis showed that elevated CRP, TNF-α, and IL-6 were the most commonly found inflammatory indicator in diabetes-related angiopathies, while increased IL-10 and soluble RAGE was an indicator for better outcome. Use of drugs such as salsalate, pioglitazone, simvastatin, and fenofibrate but not glimepiride or benfotiamine reported a significant decrease in inflammatory events. Regular exercise and consumption of dietary supplements such as ginger, hesperidin which have anti-inflammatory properties, and those containing prebiotic fibers (e.g., raspberries) revealed a consistent significant (p < 0.05) reduction in inflammatory activities.Conclusion: Inflammatory activities are implicated in diabetes-related angiopathies; regular exercise, the intake of healthy dietary supplements, and medications with anti-inflammatory properties could result in improved protective risk outcome for diabetes patients by suppressing inflammatory activities and elevating anti-inflammatory events.

Download Full-text

Dapagliflozin in the management of type 2 diabetes mellitus: a real-life experience in Bangladesh

BIRDEM Medical Journal ◽

10.3329/birdem.v11i1.51031 ◽

2020 ◽

Vol 11 (1) ◽

pp. 57-62

Author(s):

Mohammad Feroz Amin ◽

Faria Afsana ◽

Sultana Marufa Shefin ◽

Shahjada Selim ◽

Mahboob Ifhtekhar

Keyword(s):

Type 2 Diabetes ◽

Life Experience ◽

Real Life ◽

Diabetic Patients ◽

Base Line ◽

Open Label ◽

Type 2 Diabetic Patients ◽

Life Study ◽

Type 2 Diabetic

Background: Dapagliflozin, a selective renal sodium-glucose cotransporter-2 inhibitor (SGLT2i), lowers plasma glucose by increasing urinary excretion of glucose. This study evaluated the efficacy and safety of dapagliflozin as add on therapy for a selected group of Bangladeshi type 2 diabetic patients. Methods: This was a 24-week, open-label, prospective, real-life study including type 2 diabetic patients with glycated hemoglobin (HbA1c) 7.0–10% (N =53). Study subjects were selectively assigned to dapagliflozin 5 mg once-daily in the morning along with ongoing oral anti-diabetic drug (OAD). The primary end point was to see the safety (adverse events) and efficacy (reduction of fasting and post-prandial blood glucose, HbA1c) of dapagliflozin. Results: Mean HbA1c changes from baseline to week 24 was – 1.15 ± 0.82 % (P = 0.000) and weight reduction was – 2.49 ± 0.32 kg from base line (P=0.000). Among total study subjects, 6 (11.3 %) had developed urinary tract infection (UTI). There were no major episodes of hypoglycemia or renal function deterioration. Conclusion: Dapagliflozin showed significant reduction of HbA1c as add on therapy. The low incidence of hypoglycemia and UTI make dapagliflozin as an acceptable addition to existing treatment option for type 2 diabetes in Bangladeshi population. Birdem Med J 2021; 11(1): 57-62

Download Full-text